<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intraperitoneal antibiotic dosing recommendations for intermittent administration in adult patients on peritoneal dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intraperitoneal antibiotic dosing recommendations for intermittent administration in adult patients on peritoneal dialysis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intraperitoneal antibiotic dosing recommendations for intermittent administration in adult patients on peritoneal dialysis</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1_left"> </td> <td class="subtitle1_left">IP dose instilled in the longest dwell of the day of at least 6 hours</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Aminoglycosides<sup>*</sup></td> </tr> <tr> <td class="indent1">Amikacin</td> <td>2 mg/kg in one exchange per day<sup>¶</sup></td> </tr> <tr> <td class="indent1">Gentamicin</td> <td>0.6 mg/kg in one exchange per day<sup>¶</sup></td> </tr> <tr> <td class="indent1">Netilmicin<sup>Δ</sup></td> <td>0.6 mg/kg in one exchange per day<sup>¶</sup></td> </tr> <tr> <td class="indent1">Tobramycin</td> <td>0.6 mg/kg in one exchange per day<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="2">Carbapenems</td> </tr> <tr> <td class="indent1">Imipenem-cilastatin</td> <td>500 mg in alternate exchanges<sup>◊</sup></td> </tr> <tr> <td class="indent1">Meropenem</td> <td>1 gram in one exchange per day</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Cephalosporins<sup>¶</sup></td> </tr> <tr> <td class="indent1">Cefazolin</td> <td>15 to 20 mg/kg in one exchange per day</td> </tr> <tr> <td class="indent1">Cefepime</td> <td>1 gram in one exchange per day</td> </tr> <tr> <td class="indent1">Cefotaxime</td> <td>500 to 1000 mg in one exchange per day</td> </tr> <tr> <td class="indent1">Ceftazidime</td> <td>1 to 1.5 grams in one exchange per day</td> </tr> <tr> <td class="indent1">Ceftriaxone</td> <td>1 gram in one exchange per day</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Glycopeptides</td> </tr> <tr> <td class="indent1">Vancomycin</td> <td>25 mg/kg ideal body weight; re-dose once serum level is ≤15 mcg/mL<sup>§</sup></td> </tr> <tr> <td class="indent1">Teicoplanin<sup>Δ</sup></td> <td>15 mg/kg in one exchange every 5 days</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Penicillins</td> </tr> <tr> <td colspan="2"><strong>NOTE:</strong> For dosing of most penicillins for IP administration, refer to separately available UpToDate table for continuous administration of IP antibiotics.</td> </tr> <tr> <td class="indent1">Amoxicillin</td> <td><strong>Oral:</strong> 500 mg every 8 hours</td> </tr> <tr> <td class="indent1">Ampicillin<sup>¥</sup></td> <td>4 grams in one exchange per day</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Other</td> </tr> <tr> <td class="indent1">Aztreonam</td> <td>2 grams in one exchange per day</td> </tr> <tr> <td class="indent1">Ciprofloxacin<sup>‡</sup></td> <td><strong>Oral:</strong> 250 mg twice per day</td> </tr> <tr> <td class="indent1">Daptomycin</td> <td>300 mg in one exchange per day</td> </tr> <tr> <td class="indent1">Fosfomycin<sup>†</sup></td> <td>4 grams in one exchange per day</td> </tr> <tr> <td class="indent1">Linezolid</td> <td><strong>Oral:</strong> 600 mg twice per day</td> </tr> <tr> <td class="indent1">Moxifloxacin<sup>‡</sup></td> <td><strong>Oral:</strong> 400 mg once per day</td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td><strong>Oral:</strong> One double-strength tablet (trimethoprim 160 mg and sulfamethoxazole 800 mg) two times per day</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Antifungal</td> </tr> <tr> <td class="indent1">Fluconazole</td> <td>200 mg in one exchange every 24 to 48 hours</td> </tr> <tr> <td class="indent1">Voriconazole</td> <td>2.5 mg/kg in one exchange per day</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table shows the suggested dose of antibiotics for intermittent IP administration (except where noted as "oral") in peritoneal dialysate for continuous ambulatory peritoneal dialysis-associated peritonitis without signs of systemic infection. Intermittent IP-administered regimens are preferred over continuous administration (ie, antibiotics in all exchanges) for initial therapy and should be used for the duration of treatment of 2 to 3 weeks or more in patients who are responding clinically. In patients who are not improving on intermittent therapy with agent(s) that should be effective based on microbiologic data, it is reasonable to increase frequency of intermittent dosing or switch to a continuous IP dosing regimen as listed on a separately available UpToDate table. Refer to UpToDate topic on microbiology and therapy of peritonitis in continuous peritoneal dialysis for considerations in selection of antimicrobials and dosing strategy.</div><div class="graphic_footnotes"><p>IP: intraperitoneal.</p>
<p>* To determine weight-based dose of aminoglycosides in patients who are overweight, use "ideal body weight"; if obese, use "dosing weight." A calculator for determining "ideal body weight" and "dosing weight" based on inputs of actual body weight and height is available in UpToDate.</p>
<p>¶ Systemic toxicity can occur with prolonged or repeated course(s) of IP-administered aminoglycosides. Once culture and sensitivity results are available, early switch to another appropriate class of antibiotic is suggested to decrease the risk of toxicity. Refer to UpToDate topics on microbiology and therapy of peritonitis in peritoneal dialysis.</p>
<p>Δ Not available in the United States.</p>
<p>◊ Dose is expressed as mg of imipenem.</p>
<p>§ Obtain daily vancomycin serum levels. Re-dose once the serum level reaches ≤15 mcg/mL, which usually occurs within 4 to 7 days following an IP-administered dose. If serum levels are available only once every 2 to 3 days, it is reasonable to re-dose once the level reaches ≤20 mcg/mL. Supplemental doses may be needed in patients receiving machine-assisted automated peritoneal dialysis.</p>
<p>¥ For enterococcal peritonitis, we avoid ampicillin because some in vitro data suggest that its activity against <em>Enterococcus</em> may be limited in peritoneal fluid.</p>
<p>‡ We generally avoid fluoroquinolones because they have significant adverse effects, increase the risk of <em>Clostridioides difficile</em> infection, and have numerous drug interactions (including with oral phosphate binders). Refer to UpToDate topics on microbiology and therapy of peritonitis in peritoneal dialysis.</p>
† In the United States, fosfomycin is not available in the formulation necessary for intraperitoneal use.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.</li>
<li>Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42:110.</li>
</ol></div><div id="graphicVersion">Graphic 60452 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
